GLP1R and type 2 diabetes mellitus: Type 2 diabetes mellitus is a major health burden globally, with increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide for glycemic control and cardiovascular risk reduction.